Association of frailty with chemotherapy toxicity in chemotherapy-naive older patients with cancer

[1] Muss HB(2007)Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience J Clin Oncol 25 3699-3704

[2] Berry DA(2006)Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer J Clin Oncol 24 4085-4091

[3] Cirrincione C(2007)FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study Cancer 110 2666-2671

[4] Budman DR(2015)The prevalence and outcomes of frailty in older cancer patients: a systematic review Ann Oncol 26 1091-1101

[5] Henderson IC(2014)The impact of low-grade toxicity in older people with cancer undergoing chemotherapy Br J Cancer 111 2224-2228

[6] Citron ML(2014)International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer J Clin Oncol 32 2595-2603

[7] Goldberg RM(2013)Frailty consensus: a call to action J Am Med Dir Assoc 14 392-397

[8] Tabah-Fisch I(2015)Estimating the risk of chemotherapy toxicity in older patients with cancer: the role of the Vulnerable Elders Survey-13 (VES-13) J Geriatr Oncol 6 272-279

[9] Bleiberg H(2017)A comparison of the CARG tool, the VES-13, and oncologist judgment in predicting grade 3+ toxicities in men undergoing chemotherapy for metastatic prostate cancer J Geriatr Oncol 8 31-36

[10] de Gramont A(2014)Geriatric screening results and the association with severe treatment toxicity after the first cycle of (radio) chemotherapy Journal of geriatric oncology 5 179-184

[1] Muss HB(2007)Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience J Clin Oncol 25 3699-3704

[2] Berry DA(2006)Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer J Clin Oncol 24 4085-4091

[3] Cirrincione C(2007)FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study Cancer 110 2666-2671

[4] Budman DR(2015)The prevalence and outcomes of frailty in older cancer patients: a systematic review Ann Oncol 26 1091-1101

[5] Henderson IC(2014)The impact of low-grade toxicity in older people with cancer undergoing chemotherapy Br J Cancer 111 2224-2228

[6] Citron ML(2014)International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer J Clin Oncol 32 2595-2603

[7] Goldberg RM(2013)Frailty consensus: a call to action J Am Med Dir Assoc 14 392-397

[8] Tabah-Fisch I(2015)Estimating the risk of chemotherapy toxicity in older patients with cancer: the role of the Vulnerable Elders Survey-13 (VES-13) J Geriatr Oncol 6 272-279

[9] Bleiberg H(2017)A comparison of the CARG tool, the VES-13, and oncologist judgment in predicting grade 3+ toxicities in men undergoing chemotherapy for metastatic prostate cancer J Geriatr Oncol 8 31-36

[10] de Gramont A(2014)Geriatric screening results and the association with severe treatment toxicity after the first cycle of (radio) chemotherapy Journal of geriatric oncology 5 179-184